Resverlogix Corp., a clinical stage biotechnology company, develops small molecule therapeutics for Bromodomain and ExtraTerminal (BET) inhibition. The company is developing apabetalone (RVX-208), a small molecule selective BET domain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, Alzheimer s disease, and orphan diseases. Resverlogix Corp. is headquartered in Calgary, Canada.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/26/2018 12:36 PST] RESVERLOGIX CORP (OTC:RVXCF), Up By 11.63% ($0.15) After BUYINS.NET SqueezeTrigger Report Released on Thursday, February 22nd 2018 at a Price of $1.316.
• [02/22/2018 12:15 PST] RVXCF SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.